
    
      The aim of this study is to investigate the efficacy of transdermal testosterone nanoemulsion
      (TNT) as a treatment for SSRI/SNRI-emergent loss of libido.

      The primary outcome measures to be evaluated is the change in the Sabbatsberg Sexual
      Self-rating Scale (SSS) total score over 12 weeks. The 4-week frequency of Satisfactory
      Sexual Events (SSEs) and the Female Sexual Distress Scale-Revised (FSDS-R) will be also
      evaluate.
    
  